Raras
Buscar doenças, sintomas, genes...
Cardiomiopatia arritmogênica isolada hereditária
ORPHA:217656CID-10 · I42.8CID-11 · BC43.6DOENÇA RARA

A Displasia Arritmogênica do Ventrículo Direito (DAVD) Familiar é o tipo de DAVD de origem genética, passado de pais para filhos com um padrão de herança autossômico dominante. É uma doença do músculo do coração marcada por arritmias ventriculares (batimentos cardíacos irregulares e perigosos que vêm das câmaras inferiores do coração) que podem ser fatais, apresentando um padrão elétrico específico chamado bloqueio de ramo esquerdo. Os sintomas podem incluir palpitações, taquicardia ventricular (batimentos muito acelerados), desmaios e até morte súbita. A doença é causada pela degeneração e substituição do músculo do ventrículo direito por tecido gorduroso e fibroso, o que pode resultar na formação de dilatações ou "sacos" na parede desse ventrículo (aneurismas).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Displasia Arritmogênica do Ventrículo Direito (DAVD) Familiar é o tipo de DAVD de origem genética, passado de pais para filhos com um padrão de herança autossômico dominante. É uma doença do músculo do coração marcada por arritmias ventriculares (batimentos cardíacos irregulares e perigosos que vêm das câmaras inferiores do coração) que podem ser fatais, apresentando um padrão elétrico específico chamado bloqueio de ramo esquerdo. Os sintomas podem incluir palpitações, taquicardia ventricular (batimentos muito acelerados), desmaios e até morte súbita. A doença é causada pela degeneração e substituição do músculo do ventrículo direito por tecido gorduroso e fibroso, o que pode resultar na formação de dilatações ou "sacos" na parede desse ventrículo (aneurismas).

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
No data available
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: I42.8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

❤️
Coração
23 sintomas
🧬
Pele e cabelo
2 sintomas
🧠
Neurológico
1 sintomas
🫁
Pulmão
1 sintomas

+ 18 sintomas em outras categorias

Características mais comuns

Bloqueio atrioventricular
Substituição gordurosa do tecido miocárdico ventricular
Anomalia esquelética
Arritmia atrial
Fibrose miocárdica
Complexo QRS prolongado
45sintomas
Sem dados (45)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 45 características clínicas mais associadas, ordenadas por frequência.

Bloqueio atrioventricularAtrioventricular block
Substituição gordurosa do tecido miocárdico ventricularFatty replacement of ventricular myocardial tissue
Anomalia esqueléticaHP:6000666
Arritmia atrialAtrial arrhythmia
Fibrose miocárdicaMyocardial fibrosis

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Últimos 10 anos40publicações
Pico202512 papers
Linha do tempo
2026Hoje · 2026🧪 2016Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

14 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

PLNPhospholambanCandidate gene tested inModerado
FUNÇÃO

Reversibly inhibits the activity of ATP2A2/SERCA2 in cardiac sarcoplasmic reticulum by decreasing the apparent affinity of the ATPase for Ca(2+) (PubMed:28890335). Binds preferentially to the ATP-bound E1 conformational form of ATP2A2 which predominates at low Ca(2+) concentrations during the diastolic phase of the cardiac cycle (By similarity). Inhibits ATP2A2 Ca(2+) affinity by disrupting its allosteric activation by ATP (By similarity). Modulates the contractility of the heart muscle in respo

LOCALIZAÇÃO

Endoplasmic reticulum membraneSarcoplasmic reticulum membraneMitochondrion membraneMembrane

VIAS BIOLÓGICAS (2)
Ion homeostasisIon transport by P-type ATPases
MECANISMO DE DOENÇA

Cardiomyopathy, dilated, 1P

A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
902.6 TPM
Coração - Ventrículo esquerdo
804.3 TPM
Aorta
764.7 TPM
Artéria coronária
567.4 TPM
Coração - Átrio
508.7 TPM
OUTRAS DOENÇAS (4)
hypertrophic cardiomyopathy 18dilated cardiomyopathy 1Pfamilial isolated dilated cardiomyopathyfamilial isolated arrhythmogenic ventricular dysplasia, right dominant form
HGNC:9080UniProt:P26678
LDB3LIM domain-binding protein 3Candidate gene tested inTolerante
FUNÇÃO

May function as an adapter in striated muscle to couple protein kinase C-mediated signaling via its LIM domains to the cytoskeleton

LOCALIZAÇÃO

Cytoplasm, perinuclear regionCell projection, pseudopodiumCytoplasm, cytoskeletonCytoplasm, myofibril, sarcomere, Z line

MECANISMO DE DOENÇA

Cardiomyopathy, dilated, 1C, with or without left ventricular non-compaction

A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. Cardiomyopathy dilated type 1C is associated with left ventricular non-compaction in some patients. Left ventricular non-compaction is characterized by numerous prominent trabeculations and deep intertrabecular recesses in hypertrophied and hypokinetic segments of the left ventricle.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
372.3 TPM
Músculo esquelético
338.8 TPM
Coração - Átrio
299.7 TPM
Artéria tibial
89.9 TPM
Aorta
57.8 TPM
OUTRAS DOENÇAS (7)
myofibrillar myopathy 4dilated cardiomyopathy 1Cfamilial isolated arrhythmogenic ventricular dysplasia, left dominant formfamilial isolated arrhythmogenic ventricular dysplasia, biventricular form
HGNC:15710UniProt:O75112
RYR2Ryanodine receptor 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering cardiac muscle contraction. Aberrant channel activation can lead to cardiac arrhythmia. In cardiac myocytes, calcium release is triggered by increased Ca(2+) cytosolic levels due to activation of the L-type calcium channel CACNA1C. The calcium channel activity is modulated by formation of heterotetramers with RYR3. Required fo

LOCALIZAÇÃO

Sarcoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Ion homeostasisStimuli-sensing channels
MECANISMO DE DOENÇA

Ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy

An arrhythmogenic disorder characterized by stress-induced, bidirectional ventricular tachycardia that may degenerate into cardiac arrest and cause sudden death. Patients present with recurrent syncope, seizures, or sudden death after physical activity or emotional stress. CPVT1 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
82.3 TPM
Coração - Átrio
75.8 TPM
Cerebelo
27.9 TPM
Cérebro - Hemisfério cerebelar
26.5 TPM
Artéria tibial
18.5 TPM
OUTRAS DOENÇAS (6)
catecholaminergic polymorphic ventricular tachycardia 1ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndromefamilial isolated arrhythmogenic ventricular dysplasia, left dominant formfamilial isolated arrhythmogenic ventricular dysplasia, right dominant form
HGNC:10484UniProt:Q92736
CDH2Cadherin-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Calcium-dependent cell adhesion protein; preferentially mediates homotypic cell-cell adhesion by dimerization with a CDH2 chain from another cell. Cadherins may thus contribute to the sorting of heterogeneous cell types. Acts as a regulator of neural stem cells quiescence by mediating anchorage of neural stem cells to ependymocytes in the adult subependymal zone: upon cleavage by MMP24, CDH2-mediated anchorage is affected, leading to modulate neural stem cell quiescence. Plays a role in cell-to-

LOCALIZAÇÃO

Cell membraneCell membrane, sarcolemmaCell junctionCell surfaceCell junction, desmosomeCell junction, adherens junctionCell projection, axon

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Arrhythmogenic right ventricular dysplasia, familial, 14

A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias.

OUTRAS DOENÇAS (4)
attention deficit-hyperactivity disorder 8arrhythmogenic right ventricular dysplasia, familial, 14agenesis of corpus callosum, cardiac, ocular, and genital syndromefamilial isolated arrhythmogenic ventricular dysplasia, right dominant form
HGNC:1759UniProt:P19022
DSG2Desmoglein-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion (PubMed:17559062, PubMed:38395410). Involved in the interaction of plaque proteins and intermediate filaments mediating cell-cell adhesion. Required for proliferation and viability of embryonic stem cells in the blastocyst, thereby crucial for progression of post-implantation embryonic development (By similarity). Maintains pluripotency by regulating epithelial to mesenchymal transition/m

LOCALIZAÇÃO

Cell membraneCell junction, desmosomeCytoplasm

VIAS BIOLÓGICAS (6)
Apoptotic cleavage of cell adhesion proteinsKeratinizationFormation of the cornified envelopeRAC3 GTPase cycleRHOG GTPase cycle
MECANISMO DE DOENÇA

Arrhythmogenic right ventricular dysplasia, familial, 10

A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula salivar
42.9 TPM
Cólon transverso
37.5 TPM
Mama
34.1 TPM
Adipose Visceral Omentum
25.6 TPM
Intestino delgado
25.6 TPM
OUTRAS DOENÇAS (6)
dilated cardiomyopathy 1BBarrhythmogenic right ventricular dysplasia 10familial isolated arrhythmogenic ventricular dysplasia, left dominant formfamilial isolated arrhythmogenic ventricular dysplasia, biventricular form
HGNC:3049UniProt:Q14126
CTNNA3Catenin alpha-3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in formation of stretch-resistant cell-cell adhesion complexes

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell junction, desmosome

MECANISMO DE DOENÇA

Arrhythmogenic right ventricular dysplasia, familial, 13

A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Spinal cord cervical c-1
29.3 TPM
Substância negra
10.1 TPM
Nervo tibial
6.3 TPM
Hipocampo
5.6 TPM
Coração - Ventrículo esquerdo
4.7 TPM
OUTRAS DOENÇAS (4)
arrhythmogenic right ventricular dysplasia 13familial isolated arrhythmogenic ventricular dysplasia, biventricular formfamilial isolated arrhythmogenic ventricular dysplasia, left dominant formfamilial isolated arrhythmogenic ventricular dysplasia, right dominant form
HGNC:2511UniProt:Q9UI47
LMNAPrelamin-A/CCandidate gene tested inAltamente restrito
FUNÇÃO

Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane (PubMed:10080180, PubMed:10580070, PubMed:10587585, PubMed:10814726, PubMed:11799477, PubMed:12075506, PubMed:12927431, PubMed:15317753, PubMed:18551513, PubMed:18611980, PubMed:2188730, PubMed:22431096, PubMed:2344612, PubMed:23666920, PubMed:24741066, PubMed:31434876, PubMed:

LOCALIZAÇÃO

Nucleus laminaNucleus envelopeNucleus, nucleoplasmNucleus matrixNucleus speckle

VIAS BIOLÓGICAS (1)
Initiation of Nuclear Envelope (NE) Reformation
MECANISMO DE DOENÇA

Emery-Dreifuss muscular dystrophy 2, autosomal dominant

A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
392.7 TPM
Aorta
300.6 TPM
Skin Not Sun Exposed Suprapubic
297.7 TPM
Skin Sun Exposed Lower leg
272.6 TPM
Útero
255.8 TPM
OUTRAS DOENÇAS (23)
restrictive dermopathy 2familial partial lipodystrophy, Dunnigan typedilated cardiomyopathy-hypergonadotropic hypogonadism syndromemandibuloacral dysplasia with type A lipodystrophy
HGNC:6636UniProt:P02545
DSC2Desmocollin-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion (PubMed:33596089). Promotes timely incorporation of DSG2 into desmosome intercellular junctions and promotes interaction of desmosome cell junctions with intermediate filament cytokeratin, via modulation of DSP phosphorylation (PubMed:33596089). Plays an important role in desmosome-mediated maintenance of intestinal epithelial cell intercellular adhesion strength and barrier function (Pub

LOCALIZAÇÃO

Cell membraneCell junction, desmosome

VIAS BIOLÓGICAS (1)
Formation of the cornified envelope
MECANISMO DE DOENÇA

Arrhythmogenic right ventricular dysplasia, familial, 11

A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias.

EXPRESSÃO TECIDUAL(Tecido-específico)
Esôfago - Mucosa
113.9 TPM
Vagina
87.8 TPM
Glândula salivar
13.8 TPM
Cólon transverso
9.2 TPM
Intestino delgado
7.0 TPM
OUTRAS DOENÇAS (4)
arrhythmogenic right ventricular dysplasia 11familial isolated arrhythmogenic ventricular dysplasia, biventricular formfamilial isolated arrhythmogenic ventricular dysplasia, right dominant formfamilial isolated arrhythmogenic ventricular dysplasia, left dominant form
HGNC:3036UniProt:Q02487
TMEM43Transmembrane protein 43Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May have an important role in maintaining nuclear envelope structure by organizing protein complexes at the inner nuclear membrane. Required for retaining emerin at the inner nuclear membrane (By similarity). Plays a role in the modulation of innate immune signaling through the cGAS-STING pathway by interacting with RNF26 (PubMed:32614325). In addition, functions as a critical signaling component in mediating NF-kappa-B activation by acting downstream of EGFR and upstream of CARD10 (PubMed:27991

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus inner membraneCell membrane

MECANISMO DE DOENÇA

Arrhythmogenic right ventricular dysplasia, familial, 5

A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
247.5 TPM
Artéria tibial
212.8 TPM
Útero
192.2 TPM
Artéria coronária
180.6 TPM
Fibroblastos
178.4 TPM
OUTRAS DOENÇAS (7)
Emery-Dreifuss muscular dystrophy 7, autosomal dominantarrhythmogenic right ventricular dysplasia 5auditory neuropathy, autosomal dominant 3familial isolated arrhythmogenic ventricular dysplasia, left dominant form
HGNC:28472UniProt:Q9BTV4
TGFB3Transforming growth factor beta-3 proproteinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transforming growth factor beta-3 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-3 (TGF-beta-3) chains, which constitute the regulatory and active subunit of TGF-beta-3, respectively Required to maintain the Transforming growth factor beta-3 (TGF-beta-3) chain in a latent state during storage in extracellular matrix (By similarity). Associates non-covalently with TGF-beta-3 and regulates its activation via interaction with 'milieu molecules', su

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrixSecreted

VIAS BIOLÓGICAS (4)
Molecules associated with elastic fibresTGF-beta receptor signaling activates SMADsPlatelet degranulation ECM proteoglycans
MECANISMO DE DOENÇA

Arrhythmogenic right ventricular dysplasia, familial, 1

A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
77.8 TPM
Próstata
67.8 TPM
Cervix Ectocervix
57.8 TPM
Útero
46.5 TPM
Aorta
40.5 TPM
OUTRAS DOENÇAS (7)
Rienhoff syndromearrhythmogenic right ventricular dysplasia 1familial isolated arrhythmogenic ventricular dysplasia, right dominant formLoeys-Dietz syndrome
HGNC:11769UniProt:P10600
DSPDesmoplakinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion (PubMed:25733715). Critical for cell-cell adhesion in early stage blastocysts and progression through proamniotic cavity formation (By similarity). Not required for preimplantation morphogenic process in blastocysts (By similarity). Required for keratin filament anchoring at the desmosome junction and subsequent organization of the keratin intermediate filament network within the cytoplas

LOCALIZAÇÃO

Cell projection, axonCell junction, desmosomeCell membraneCytoplasmNucleus

VIAS BIOLÓGICAS (6)
Apoptotic cleavage of cell adhesion proteinsNeutrophil degranulationKeratinizationFormation of the cornified envelopeRND1 GTPase cycle
MECANISMO DE DOENÇA

Keratoderma, palmoplantar, striate 2

A dermatological disorder characterized by thickening of the skin on the palms (linear pattern) and the soles (island-like pattern) and flexor aspect of the fingers. Abnormalities of the nails, the teeth and the hair are rarely present.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
1294.4 TPM
Skin Not Sun Exposed Suprapubic
1155.3 TPM
Esôfago - Mucosa
647.4 TPM
Vagina
416.9 TPM
Glândula salivar
87.7 TPM
OUTRAS DOENÇAS (13)
arrhythmogenic cardiomyopathy with wooly hair and keratodermakeratosis palmoplantaris striata 2lethal acantholytic epidermolysis bullosacardiomyopathy, dilated, with wooly hair, keratoderma, and tooth agenesis
HGNC:3052UniProt:P15924
TTNTitinCandidate gene tested inRestrito
FUNÇÃO

Key component in the assembly and functioning of vertebrate striated muscles. By providing connections at the level of individual microfilaments, it contributes to the fine balance of forces between the two halves of the sarcomere. The size and extensibility of the cross-links are the main determinants of sarcomere extensibility properties of muscle. In non-muscle cells, seems to play a role in chromosome condensation and chromosome segregation during mitosis. Might link the lamina network to ch

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Platelet degranulation
MECANISMO DE DOENÇA

Myopathy, myofibrillar, 9, with early respiratory failure

An autosomal dominant myopathy characterized by adulthood onset of weakness in proximal, distal, axial and respiratory muscles. Pelvic girdle weakness, foot drop and neck weakness are the main symptoms at onset, but ultimately the weakness usually involves the proximal compartment of both upper and lower limbs. Additional features include variable degrees of Achilles tendon contractures, spinal rigidity and muscle hypertrophy. Respiratory involvement often leads to requirement for non-invasive ventilation support.

EXPRESSÃO TECIDUAL(Tecido-específico)
Músculo esquelético
358.5 TPM
Coração - Ventrículo esquerdo
66.8 TPM
Coração - Átrio
56.9 TPM
Testículo
1.6 TPM
Pulmão
1.0 TPM
OUTRAS DOENÇAS (14)
autosomal recessive limb-girdle muscular dystrophy type 2Jmyopathy, myofibrillar, 9, with early respiratory failureearly-onset myopathy with fatal cardiomyopathydilated cardiomyopathy 1G
HGNC:12403UniProt:Q8WZ42
JUPJunction plakoglobinDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Common junctional plaque protein. The membrane-associated plaques are architectural elements in an important strategic position to influence the arrangement and function of both the cytoskeleton and the cells within the tissue. The presence of plakoglobin in both the desmosomes and in the intermediate junctions suggests that it plays a central role in the structure and function of submembranous plaques. Acts as a substrate for VE-PTP and is required by it to stimulate VE-cadherin function in end

LOCALIZAÇÃO

Cell junction, adherens junctionCell junction, desmosomeCytoplasm, cytoskeletonCell membraneCytoplasmCell junctionNucleusCell projection, axon

VIAS BIOLÓGICAS (7)
VEGFR2 mediated vascular permeabilityAdherens junctions interactionsRegulation of CDH11 functionCDH11 homotypic and heterotypic interactionsRegulation of CDH19 Expression and Function
MECANISMO DE DOENÇA

Naxos disease

An autosomal recessive disorder characterized by the association of diffuse non-epidermolytic palmoplantar keratoderma with woolly hair and cardiac abnormalities such as dilated cardiomyopathy and arrhythmogenic right ventricular dysplasia.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
1198.5 TPM
Skin Not Sun Exposed Suprapubic
1088.8 TPM
Esôfago - Mucosa
1053.2 TPM
Vagina
638.8 TPM
Glândula salivar
150.3 TPM
OUTRAS DOENÇAS (6)
Naxos diseasearrhythmogenic right ventricular dysplasia 12familial isolated arrhythmogenic ventricular dysplasia, right dominant formfamilial isolated arrhythmogenic ventricular dysplasia, left dominant form
HGNC:6207UniProt:P14923
PKP2Plakophilin-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion (PubMed:25208567). Regulates focal adhesion turnover resulting in changes in focal adhesion size, cell adhesion and cell spreading, potentially via transcriptional modulation of beta-integrins (PubMed:23884246). Required to maintain gingival epithelial barrier function (PubMed:34368962). Important component of the desmosome that is also required for localization of desmosome component pro

LOCALIZAÇÃO

NucleusCell junction, desmosomeCell junctionCytoplasm

VIAS BIOLÓGICAS (1)
Formation of the cornified envelope
MECANISMO DE DOENÇA

Arrhythmogenic right ventricular dysplasia, familial, 9

A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
66.9 TPM
Coração - Átrio
41.6 TPM
Glândula salivar
35.8 TPM
Ovário
20.1 TPM
Cólon transverso
19.3 TPM
OUTRAS DOENÇAS (6)
arrhythmogenic right ventricular dysplasia 9Brugada syndromefamilial isolated arrhythmogenic ventricular dysplasia, left dominant formfamilial isolated arrhythmogenic ventricular dysplasia, right dominant form
HGNC:9024UniProt:Q99959

Variantes genéticas (ClinVar)

1,765 variantes patogênicas registradas no ClinVar.

🧬 PLN: NM_002667.5(PLN):c.-97-6T>A ()
🧬 PLN: GRCh37/hg19 6q22.1-22.33(chr6:114742335-127346798)x1 ()
🧬 PLN: NM_002667.5(PLN):c.26G>T (p.Arg9Leu) ()
🧬 PLN: NM_002667.5(PLN):c.4G>T (p.Glu2Ter) ()
🧬 PLN: NM_002667.5(PLN):c.2T>G (p.Met1Arg) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

44 vias biológicas associadas aos genes desta condição.

Ion homeostasis Ion transport by P-type ATPases Stimuli-sensing channels Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Adherens junctions interactions Myogenesis Post-translational protein phosphorylation Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition Apoptotic cleavage of cell adhesion proteins Keratinization Formation of the cornified envelope RAC2 GTPase cycle RHOG GTPase cycle RAC3 GTPase cycle Meiotic synapsis Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation Breakdown of the nuclear lamina XBP1(S) activates chaperone genes Depolymerization of the Nuclear Lamina Signaling by BRAF and RAF1 fusions Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Platelet degranulation Molecules associated with elastic fibres TGF-beta receptor signaling activates SMADs ECM proteoglycans Neutrophil degranulation RND3 GTPase cycle RND1 GTPase cycle Striated Muscle Contraction VEGFR2 mediated vascular permeability RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOJ GTPase cycle Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane CDH11 homotypic and heterotypic interactions

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Cardiomiopatia arritmogênica isolada hereditária

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Clinical Spectrum of Arrhythmogenic Entities in Spanish Children Carrying Deleterious SCN5A Variants.

International journal of molecular sciences2026 Jan 15

Deleterious variants in SCN5A lead to a wide clinical spectrum that includes pathologies characterized by life-threatening cardiac events (CEs). In the pediatric population, early identification, management, and risk stratification of these pathologies are the main current challenges. This study analyzed a Spanish pediatric cohort (≤18 years) carrying rare SCN5A variants to explore genotype-phenotype correlations. A retrospective descriptive cohort study, including clinical, demographic, and genetic data of probands and their relatives, was conducted. Out of 100 children studied, 69 had definitively deleterious SCN5A variants (26 females, 38%; median age: 3 years, IQR 1-12). The main diagnoses were isolated Brugada syndrome (BrS) (31; 45%); isolated long QT syndrome type 3 (LQT3) (5; 7%); isolated progressive cardiac conduction disease (PCCD) (1; 2%); isolated familial atrial fibrillation (1; 2%); overlapping phenotypes (7; 10%) including: BrS-PCCD (2; 2.8%); BrS-LQT3 (1; 1.4%); premature ventricular contraction-dilated cardiomyopathy (1; 1.4%); BrS-LQT3-PCCD (1; 1.4%); BrS-PCCD-sick sinus syndrome (SSS) (1; 1.4%) and BrS-PCCD-SSS-familial atrial fibrillation (1; 1.4%). Of them, 13 (19%) patients presented with CEs (cardiogenic syncope, ventricular tachycardia/fibrillation, sudden cardiac arrest/death, and appropriate implantable cardio defibrillator shock). These findings underscore the utility of genetic testing for early diagnosis, risk stratification, and personalized management, enhancing preventive strategies for CE prevention in pediatrics.

#2

Chemotherapy-Induced Arrhythmogenic Right Ventricular Cardiomyopathy.

JACC. Case reports2026 Feb 18

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disorder characterized by fibrofatty replacement of the right ventricular myocardium. Anthracycline-induced cardiotoxicity typically manifests as left ventricular dysfunction; however, we present a unique case of an acquired ARVC phenotype secondary to anthracycline chemotherapy exposure. A 74-year-old man developed recurrent exertional syncope 8 months after completing rituximab, cyclophosphamide, hydroxydaunorubicin (an anthracycline that is also known as doxorubicin), oncovin, and prednisone chemotherapy. He met 3 major 2010 Revised Task Force Criteria for definite ARVC, despite negative genetic testing and absence of family history. He underwent dual-chamber implantable cardioverter-defibrillator implantation with complete resolution of syncopal episodes. Recognition of acquired ARVC after anthracycline exposure broadens the spectrum of chemotherapy-related cardiomyopathies and calls for vigilance in patients with unexplained right ventricular dysfunction or arrhythmias after chemotherapy. Anthracyclines may cause isolated right ventricular dysfunction mimicking ARVC. Clinicians should maintain vigilance for right ventricular dysfunction or arrhythmias in patients after anthracycline therapy.

#3

Isolated Nonischemic Left Ventricular Scar in Asymptomatic Athletes: Clinical Characteristics, Genetic Background, and Follow-Up.

JACC. Clinical electrophysiology2026 Jan 05

Isolated nonischemic left ventricular scar (NILVS), identified by cardiac magnetic resonance, is an increasing finding in athletes and may be the substrate for life-threatening arrhythmias. Clinical significance in asymptomatic athletes is yet to be investigated. This study sought to describe the clinico-genetic profile and follow-up of asymptomatic athletes diagnosed with NILVS through preparticipation screening. We evaluated 40 athletes (90% males, 44 [range:33-52] years) including 9 elites, with isolated NILVS involving at least 2 segments, no previous major arrhythmic events, with available genetic testing and >1 year of follow-up. Data regarding electrocardiography, echocardiography, 24-hour Holter, exercise testing, and genetic analysis were collected. Follow-up assessed therapy, sport participation, and outcome. Electrocardiogram abnormalities were present in 48%, and all showed premature ventricular beats at exercise testing, mostly with right bundle branch/superior axis morphology. Left ventricular ejection fraction was normal or mildly reduced. Genetic testing or family screening was positive in 9 (23%). Athletes without familial/genetic background were older and declared higher cumulative years of sports activity. Over a median follow-up time of 23 months, 84% continued noncompetitive sport, mostly (73%) on beta-blocker therapy. Two major arrhythmic events occurred (resuscitated cardiac arrest and sustained ventricular tachycardia), both in athletes with a positive family history for NILVS, but negative genetic testing, and both during noncompetitive exercise. NILVS in asymptomatic athletes may carry arrhythmic risk even in the absence of previous symptoms or left ventricular dysfunction. Athletes with NILVS and no gene mutations/family history are older and with a higher past exercise volume.

#4

Apremilast improves cardiomyocyte cohesion and arrhythmia in different models for arrhythmogenic cardiomyopathy.

Stem cell research &amp; therapy2025 Nov 04

Arrhythmogenic cardiomyopathy (ACM) is a genetically inherited desmosome heart disease leading to life-threatening arrhythmias and sudden cardiac death. Currently, ACM treatment paradigms are merely symptom targeting. Recently, apremilast was shown to stabilize keratinocyte adhesion in the desmosomal disease pemphigus vulgaris. Therefore, this study investigated whether apremilast can be a therapeutic option for ACM. Human induced pluripotent stem cells from a healthy control (hiPSC) and an ACM index patient (ACM-hiPSC) carrying a heterozygous desmoplakin (DSP) gene mutation (c.2854G > T, p.Glu952Ter), confirmed by whole exome sequencing (WES), were established. Cyclic-AMP ELISA, dissociation assay, immunostaining, and Western blotting analyses were performed in human iPSC-derived cardiomyocytes (hiPSC-CMs), murine HL-1 cardiomyocytes, and cardiac slices derived from wild-type (WT) mice, plakoglobin (PG, Jup) knockout (Jup-/-) (murine ACM model) or PG Serine 665 phosphodeficient (JUP-S665A) mice. Microelectrode array (MEA) analyses in ventricular cardiac slices and Langendorff heart perfusion were performed to analyze heart rate variability and arrhythmia. ACM-hiPSC derived cardiomyocytes (ACM-hiPSC-CMs) revealed a significant loss of cohesion, which was rescued by apremilast. Further, treatment with apremilast strengthened basal cardiomyocyte cohesion in HL-1 cells and WT murine cardiac slices, paralleled by phosphorylation of PG at Serine 665 in human and murine models. In HL-1 cells, apremilast in addition activated ERK1/2, inhibition of which abolished apremilast-enhanced cardiomyocyte cohesion. Further, dissociation assays in slice cultures from JUP-S665A and Jup-/- mice revealed that PG is crucial for apremilast-enhanced cardiomyocyte cohesion. In parallel to enhanced cell adhesion, MEA and Langendorff measurements from WT and Jup-/- mice demonstrated decreased heart rate variability and arrhythmia after apremilast treatment. Apremilast improves loss of cardiomyocyte cohesion, enhances localization of DSG2, and reduces arrhythmia in human and/or murine models of ACM ex vivo and in vitro, providing a novel treatment strategy for ACM by preserving desmosome function.

#5

Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.

Circulation2025 Dec 16

Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac disorder marked by left ventricular hypertrophy and hypercontractility. This excessive mechanical workload creates an energetic mismatch in which consumption exceeds production, leading to myocardial energy depletion. Although CK (creatine kinase) plays a key role in cardiac energy homeostasis, its involvement in HCM remains unclear. This study investigates how hypercontractility-driven mitochondrial stress and the resulting increase in mitochondrial H2O2 disrupt CK function in HCM. CK function was analyzed using myocardial left ventricular tissue from 92 patients with HCM (with and without pathogenic sarcomere variants) and 30 non-failing human controls. Myofilament and mitochondrial CK isoforms were measured using mRNA analysis, protein immunoblotting, enzyme activity assays, mass spectrometry, and redox-sensitive proteomics. To explore links between hypercontractility, mitochondrial reactive oxygen species, and CK dysfunction, we used isolated cardiomyocytes from wild-type, mitochondrial-targeted catalase-overexpressing, CK knockout (myofilament and mitochondrial CK deletion), HCM-associated Mybpc3 knock-in, and mito-roGFP2-Orp1 mouse models. We also tested the effects of the Ca2+ sensitizer EMD-57033, the CK inhibitor 1-fluoro-2,4-dinitrobenzene (DNFB), and the myosin inhibitor MYK-581, a mavacamten derivative. Our analysis revealed significant reductions in myofilament and mitochondrial CK protein levels, as well as CK activity, in myocardium of patients with HCM, primarily because of oxidative modifications of CK. In isolated mouse cardiomyocytes from wild-type and CK knockouts, hypercontractility induced by EMD-57033 elevated mitochondrial H2O2, causing cellular arrhythmias and CK inactivation. Hypercontractility-induced oxidative stress, arrhythmias, and CK dysfunction were also observed in Mybpc3 knock-in cardiomyocytes. Mitochondrial-targeted catalase-overexpressing mice with enhanced H2O2 scavenging were protected against H2O2-induced (EMD-57033-mediated) arrhythmias and CK dysfunction. MYK-581 treatment in Mybpc3 knock-in cardiomyocytes reduced hypercontractility, lowered H2O2 production and arrhythmias, and preserved CK function. CK inhibition using DNFB in wild-type cardiomyocytes elevated mitochondrial H2O2 levels and triggered cellular arrhythmias. This mitochondrial oxidation was independently confirmed in mito-roGFP2-Orp1 cardiomyocytes exposed to DNFB. Mitochondrial-targeted catalase-overexpressing mice were protected from DNFB-induced oxidative stress and arrhythmogenic events. This study reveals a mechanistic link between hypercontractility, mitochondrial reactive oxygen species, and CK dysfunction in HCM, perpetuating a cycle of energetic dysfunction. Targeting hypercontractility and oxidative stress through myosin inhibition offers a strategy to restore energy balance and reduce arrhythmic risk in HCM.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 40

2026

Chemotherapy-Induced Arrhythmogenic Right Ventricular Cardiomyopathy.

JACC. Case reports
2026

Clinical Spectrum of Arrhythmogenic Entities in Spanish Children Carrying Deleterious SCN5A Variants.

International journal of molecular sciences
2025

Arrhythmias across the tree of life: comparative insights for human electrophysiology.

Frontiers in cardiovascular medicine
2026

Isolated Nonischemic Left Ventricular Scar in Asymptomatic Athletes: Clinical Characteristics, Genetic Background, and Follow-Up.

JACC. Clinical electrophysiology
2025

Atrial Dilated Cardiomyopathy: From Molecular Pathogenesis to Clinical Implications.

Journal of clinical medicine
2025

Genetic and Clinical Characterization of FLNC Variants in Chinese Patients with Cardiomyopathy.

Journal of cardiovascular development and disease
2025

Right Ventricular Outflow Tract Diameter for Event Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy: Incremental Value Over Echocardiographic Free-Wall Strain.

JACC. Cardiovascular imaging
2025

Epicardial contributions to fibro-inflammatory signaling in a Pkp2-deficient arrhythmogenic cardiomyopathy model.

bioRxiv : the preprint server for biology
2025

Apremilast improves cardiomyocyte cohesion and arrhythmia in different models for arrhythmogenic cardiomyopathy.

Stem cell research &amp; therapy
2025

Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.

Circulation
2025

Arrhythmogenic Cardiomyopathy with Biventricular Involvement and Right Ventricular Thrombosis: A Multi-modality Imaging Approach.

Heart views : the official journal of the Gulf Heart Association
2025

NPPA-Associated Atrial Dilated Cardiomyopathy: Genotypic and Phenotypic Insights From an Ultrarare Inherited Disorder.

JACC. Case reports
2025

Diagnostic Criteria and Disease Staging for Desmoplakin Cardiomyopathy.

medRxiv : the preprint server for health sciences
2025

Arrhythmogenic Cardiomyopathy PKP2-Related: Clinical and Functional Characterization of a Pathogenic Variant Detected in Two Italian Families.

Genes
2025

Analysis of effector/memory regulatory T cells from arrhythmogenic cardiomyopathy patients identified IL-32 as a novel player in ACM pathogenesis.

Cell death &amp; disease
2024

Hyperactivation of ATF4/TGF-β1 signaling contributes to the progressive cardiac fibrosis in Arrhythmogenic cardiomyopathy caused by DSG2 Variant.

BMC medicine
2024

Extracellular Kir2.1C122Y Mutant Upsets Kir2.1-PIP2 Bonds and Is Arrhythmogenic in Andersen-Tawil Syndrome.

Circulation research
2024

Arrhythmogenic Right Ventricular Cardiomyopathy Post-Mortem Assessment: A Systematic Review.

International journal of molecular sciences
2023

Isolated JUP plakoglobin gene mutation with left ventricular fibrosis in familial arrhythmogenic right ventricular cardiomyopathy.

Journal of cardiovascular electrophysiology
2023

Desmosomal protein degradation as an underlying cause of arrhythmogenic cardiomyopathy.

Science translational medicine
2022

Concealed Substrates in Brugada Syndrome: Isolated Channelopathy or Associated Cardiomyopathy?

Genes
2022

Continuous-flow left ventricular assist device treatment for arrhythmogenic right ventricular cardiomyopathy complicated by advanced biventricular failure - University of Tokyo experiences.

Frontiers in cardiovascular medicine
2022

Identification of a novel variant in N-cadherin associated with dilated cardiomyopathy.

Frontiers in medicine
2022

Progressive Reduction in Right Ventricular Contractile Function Attributable to Altered Actin Expression in an Aging Mouse Model of Arrhythmogenic Cardiomyopathy.

Circulation
2022

Novel plasma biomarkers predicting biventricular involvement in arrhythmogenic right ventricular cardiomyopathy.

American heart journal
2021

A Case of Peripartum Ventricular Tachycardia due to Arrhythmogenic Right Ventricular Dysplasia.

South Dakota medicine : the journal of the South Dakota State Medical Association
2021

Cardiac magnetic resonance in patients with ARVC and family members: the potential role of native T1 mapping.

The international journal of cardiovascular imaging
2020

Cardiovascular Magnetic Resonance and Sport Cardiology: a Growing Role in Clinical Dilemmas.

Journal of cardiovascular translational research
2020

Overcoming challenges in the management of arrhythmogenic right ventricular cardiomyopathy.

Kardiologia polska
2020

Familial screening in case of acute myocarditis reveals inherited arrhythmogenic left ventricular cardiomyopathies.

ESC heart failure
2020

The evolution of gene-guided management of inherited arrhythmia syndromes: Peering beyond monogenic paradigms towards comprehensive genomic risk scores.

Journal of cardiovascular electrophysiology
2020

G790del mutation in DSC2 alone is insufficient to develop the pathogenesis of ARVC in a mouse model.

Biochemistry and biophysics reports
2019

Sudden Death and Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy.

Circulation
2019

Atrial fibrillation in patients with inherited cardiomyopathies.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
2018

Novel Desmin Mutation p.Glu401Asp Impairs Filament Formation, Disrupts Cell Membrane Integrity, and Causes Severe Arrhythmogenic Left Ventricular Cardiomyopathy/Dysplasia.

Circulation
2017

Arrhythmogenic Right Ventricular Dysplasia: An Under-recognized Form of Inherited Cardiomyopathy.

Reviews in cardiovascular medicine
2016

The Role of Genetic Testing in the Identification of Young Athletes with Inherited Primitive Cardiac Disorders at Risk of Exercise Sudden Death.

Frontiers in cardiovascular medicine
2016

Combination of palmoplantar keratoderma and hair shaft anomalies, the warning signal of severe arrhythmogenic cardiomyopathy: a systematic review on genetic desmosomal diseases.

Journal of medical genetics
2015

Risk Stratification in Hypertrophic Cardiomyopathy.

European cardiology
2015

Arrhythmogenic right ventricular cardiomyopathy. Contribution of cardiac magnetic resonance imaging to the diagnosis.

Herz

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Cardiomiopatia arritmogênica isolada hereditária.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Cardiomiopatia arritmogênica isolada hereditária

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Clinical Spectrum of Arrhythmogenic Entities in Spanish Children Carrying Deleterious SCN5A Variants.
    International journal of molecular sciences· 2026· PMID 41596527mais citado
  2. Chemotherapy-Induced Arrhythmogenic Right Ventricular Cardiomyopathy.
    JACC. Case reports· 2026· PMID 41709806mais citado
  3. Isolated Nonischemic Left Ventricular Scar in Asymptomatic Athletes: Clinical Characteristics, Genetic Background, and Follow-Up.
    JACC. Clinical electrophysiology· 2026· PMID 41537720mais citado
  4. Apremilast improves cardiomyocyte cohesion and arrhythmia in different models for arrhythmogenic cardiomyopathy.
    Stem cell research &amp; therapy· 2025· PMID 41185038mais citado
  5. Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.
    Circulation· 2025· PMID 41111389mais citado
  6. Peritoneal dialysis in congestive heart failure: reflections from a patient with arrhythmogenic right ventricular cardiomyopathy.
    BMJ Case Rep· 2025· PMID 40287158recente
  7. Arrhythmogenic Cardiomyopathy PKP2-Related: Clinical and Functional Characterization of a Pathogenic Variant Detected in Two Italian Families.
    Genes (Basel)· 2025· PMID 40282378recente
  8. Sudden cardiac death, arrhythmogenic cardiomyopathy and intercalated disc pathology due to reduced filamin C protein levels: a matter of life and death.
    Hum Mol Genet· 2025· PMID 39895064recente
  9. Hyperactivation of ATF4/TGF-β1 signaling contributes to the progressive cardiac fibrosis in Arrhythmogenic cardiomyopathy caused by DSG2 Variant.
    BMC Med· 2024· PMID 39227800recente
  10. Cardiac sympathetic neurons are additional cells affected in genetically determined arrhythmogenic cardiomyopathy.
    J Physiol· 2025· PMID 39141822recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:217656(Orphanet)
  2. MONDO:0016342(MONDO)
  3. GARD:17129(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q56013813(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Cardiomiopatia arritmogênica isolada hereditária
Compêndio · Raras BR

Cardiomiopatia arritmogênica isolada hereditária

ORPHA:217656 · MONDO:0016342
Prevalência
Unknown
Herança
Autosomal dominant
CID-10
I42.8 · Outras cardiomiopatias
CID-11
Início
No data available
Prevalência
0.0 (Worldwide)
UMLS
C4274968
Repurposing
1 candidato
dexrazoxanechelating agent|topoisomerase inhibitor
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades